Tue, Dec 10, 2019 · 8:30

Accelerate the Discovery, Translation & Clinical Development of Safe, Effective & Deliverable Therapies to Patients in Need

This December, 60+ thought-leaders including neuro-oncologists, neurosurgeons and oncology professionals from biopharma will be converging at the first industry led Glioblastoma Drug Development Summit under a common goal of accelerating the practical discovery, translation and clinical development of safe, effective and deliverable therapies to treat glioblastoma.

Brochure: https://go.evvnt.com/511518-3?pid=5731

Industry : USD 2699.0,
Academic : USD 1699.0

Speakers: Adilia Hormigo, Director Neuro-Oncology Division, Icahn School of Medicine , Mount Sinai & The Tisch Cancer Institute, Antonio Chiocca , Neurosurgeon-in-chief & Chairman, Brigham & Women’s, Christophe Quéva , Chief Scientific Officer, Oncorus, David Nathanson, Assistant Professor, UCLA, Douglas Jolly, Executive VP, Tocagen, Ed Reilly, Distinguished Research Fellow, AbbVie, James Garner, Chief Executive Officer & Managing Director, Kazia Therapeutics Limited, James Stuart , Medical Director, Innovate Pharmaceuticals, Jann Sarkaria , Professor of Radiation Oncology, Mayo Clinic, Jeffrey Skolnik, Vice President, Inovio Pharmaceuticals, Kirk Tanner, Chief Scientific Officer, National Brain Tumor Society (NBTS), Laurent Salphati, Principal Scientist, Genentech, Marnix Bosch, CTO, Northwest Biotherapeutics, Patrick Wen Director, Center For Neuro-Oncology, Dana-Farber/Brigham & Women’s Cancer Center, Ranjit S. Bindra, Associate Professor of Therapeutic Radiology, Yale School of Medicine, Sharon Shacham, President & Chief Scientific Officer / Co-founder, Karyopharm, Stephen Durant, Associate Principal Scientist, AstraZeneca, Susan Chang, Director, UCSF, Thomas N. Seyfried, Professor, Boston College, Timothy Cloughesy, Director, Neuro-Oncology Program, Professor UCLA, William F. Elmquist, Professor and Director of the Brain Barriers Research Center, University of Minnesota, Michael Lim, Director of the Brain Tumor Immunotherapy Program, Johns Hopkins University School of Medicine, Josep Garcia, Global Development Lead for Avastin, Roche-Genentech, Speaker to be Announced, GBM Agile Global Coalition for Adaptive Research